The mean of analysts' price targets for Summit Therapeutics (SMMT) points to a 63% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

Looking at the chart above, SMMT's low point in its 52 week range is $6.78 per share, with $36.91 as the 52 week high point — that compares with a last trade of $21.28.

An analyst's downbeat new take on Summit Therapeutics (NASDAQ: SMMT) pushed its stock downward on Hump Day. At the end of Wednesday, the shares had booked a loss of over 11% in price as investors ...

Discover real-time Summit Therapeutics Inc. Common Stock (SMMT) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.

Nasdaq Listed Alerts Market: Closed Summit Therapeutics Inc. Common Stock (SMMT) Volume: 3,910,747 52 Week Range: 6.78 - 36.91 ...

In 2024, Summit Therapeutics SMMT reported positive data from a phase III study (conducted in China by partner Akeso) in patients with locally advanced or metastatic NSCLC, in which its lead ...

View the most recent data and latest information on option chains for Summit Therapeutics Inc. Common Stock (SMMT) at Nasdaq.com.

Summit Therapeutics (SMMT) stock, a potential rival for Merck (MRK) traded lower as Leerink Partners started its coverage with a Sell-equivalent rating. Read more here.

Shares of Summit Therapeutics (NASDAQ:SMMT) ended four straight sessions of gains on Wednesday after Leerink Partners initiated its coverage with a Sell-equivalent recommendation, arguing that the ...

The latest price target for Summit Therapeutics (NASDAQ:SMMT) was reported by UBS on July 1, 2025. The analyst firm set a price target for $30.00 expecting SMMT to rise to within 12 months (a ...

However, on June 12, Leerink Partners initiated coverage with a Sell rating on Summit Therapeutics (NASDAQ: SMMT). See today’s best-performing stocks on TipRanks >> ...

NEW YORK, June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised ...